Consistent with these findings, changes in Usp22 levels impact the expression of genes regulated by the androgen receptor (AR) together with MYC in xenograft models for prostate cancer through the regulation of AR protein levels, ultimately affecting the response to therapy [12]. This evidence concerns the gene AR and prostate carcinoma.